Cerebral Infarction After Switching From Roxadustat to Daprodustat in a Patient With Renal Anemia
Renal anemia is generally caused by a decrease in the production of erythropoietin in kidney due to renal dysfunction, and this may be associated with the increase in mortality and cardiovascular events in addition to subjective symptoms such as fatigue and wobbliness. We report a case of an 87-year...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2024-07, Vol.16 (7), p.e63942 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | e63942 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 16 |
| creator | Takebayashi, Kohzo Yamauchi, Mototaka Hara, Kenji Tsuchiya, Takafumi Hashimoto, Koshi |
| description | Renal anemia is generally caused by a decrease in the production of erythropoietin in kidney due to renal dysfunction, and this may be associated with the increase in mortality and cardiovascular events in addition to subjective symptoms such as fatigue and wobbliness. We report a case of an 87-year-old man with type 2 diabetes, hypertension, and dyslipidemia who had received roxadustat (a hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor) for renal anemia due to diabetic nephropathy and in whom roxadustat was switched to daprodustat (another HIF-PH inhibitor) due to the onset of central hypothyroidism. About three weeks after this change, the patient developed acute asymptomatic cerebral infarction with an elevation of hemoglobin (Hb). It is unclear if the change to daprodustat was involved in the onset of cerebral infarction. However, this case suggests that particular caution should be paid to unexpected acute elevation of Hb after a change from one HIF-PH inhibitor to another, especially in a patient at high risk for cardiovascular events. |
| doi_str_mv | 10.7759/cureus.63942 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11227077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3076765857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-110ef6e59d0ae8f2f02f4dba9baad4eec094be3d48a08d903bed3fa7ac598e483</originalsourceid><addsrcrecordid>eNpdkUFv1DAQhSMEolXpjTOyxIUDW8ZxEtsntFpaqFQJVEAcrYkz7rra2IvtQPn3ZNmlKpxmRvPp6T29qnrO4UzKVr-xU6Ipn3VCN_Wj6rjmnVoorprHD_aj6jTnWwDgIGuQ8LQ6EkrLRuj2uMIVJeoTbthlcJhs8TGwpSuU2Oefvti1DzfsIsWRXcc7HKZcsLAS2Tvcpng4fWDIPmHxFAr75suaXVOYFZeBRo_PqicON5lOD_Ok-npx_mX1YXH18f3lanm1sAKgLDgHch21egAk5WoHtWuGHnWPODREFnTTkxgahaAGDaKnQTiUaFutqFHipHq7191O_UiDnc3Mscw2-RHTLxPRm38_wa_NTfxhOK9rCVLOCq8OCil-nygXM_psabPBQHHKRoDsZNeqdoe-_A-9jVOaQ-8o1XVSa8Fn6vWesinmnMjdu-Fgdv2ZfX_mT38z_uJhgnv4b1viN1ZsmWg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3086679931</pqid></control><display><type>article</type><title>Cerebral Infarction After Switching From Roxadustat to Daprodustat in a Patient With Renal Anemia</title><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Takebayashi, Kohzo ; Yamauchi, Mototaka ; Hara, Kenji ; Tsuchiya, Takafumi ; Hashimoto, Koshi</creator><creatorcontrib>Takebayashi, Kohzo ; Yamauchi, Mototaka ; Hara, Kenji ; Tsuchiya, Takafumi ; Hashimoto, Koshi</creatorcontrib><description>Renal anemia is generally caused by a decrease in the production of erythropoietin in kidney due to renal dysfunction, and this may be associated with the increase in mortality and cardiovascular events in addition to subjective symptoms such as fatigue and wobbliness. We report a case of an 87-year-old man with type 2 diabetes, hypertension, and dyslipidemia who had received roxadustat (a hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor) for renal anemia due to diabetic nephropathy and in whom roxadustat was switched to daprodustat (another HIF-PH inhibitor) due to the onset of central hypothyroidism. About three weeks after this change, the patient developed acute asymptomatic cerebral infarction with an elevation of hemoglobin (Hb). It is unclear if the change to daprodustat was involved in the onset of cerebral infarction. However, this case suggests that particular caution should be paid to unexpected acute elevation of Hb after a change from one HIF-PH inhibitor to another, especially in a patient at high risk for cardiovascular events.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.63942</identifier><identifier>PMID: 38974395</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Anemia ; Antibodies ; Asymptomatic ; Blood tests ; Creatinine ; Diabetes ; Diabetic nephropathy ; Endocrinology/Diabetes/Metabolism ; Hemoglobin ; Hospitalization ; Hypertension ; Internal Medicine ; Iron ; Laboratories ; Magnetic resonance imaging ; Metabolic disorders ; Pituitary gland ; Stroke ; Thrombosis ; Thyroid gland</subject><ispartof>Curēus (Palo Alto, CA), 2024-07, Vol.16 (7), p.e63942</ispartof><rights>Copyright © 2024, Takebayashi et al.</rights><rights>Copyright © 2024, Takebayashi et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2024, Takebayashi et al. 2024 Takebayashi et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-110ef6e59d0ae8f2f02f4dba9baad4eec094be3d48a08d903bed3fa7ac598e483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227077/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227077/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38974395$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takebayashi, Kohzo</creatorcontrib><creatorcontrib>Yamauchi, Mototaka</creatorcontrib><creatorcontrib>Hara, Kenji</creatorcontrib><creatorcontrib>Tsuchiya, Takafumi</creatorcontrib><creatorcontrib>Hashimoto, Koshi</creatorcontrib><title>Cerebral Infarction After Switching From Roxadustat to Daprodustat in a Patient With Renal Anemia</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Renal anemia is generally caused by a decrease in the production of erythropoietin in kidney due to renal dysfunction, and this may be associated with the increase in mortality and cardiovascular events in addition to subjective symptoms such as fatigue and wobbliness. We report a case of an 87-year-old man with type 2 diabetes, hypertension, and dyslipidemia who had received roxadustat (a hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor) for renal anemia due to diabetic nephropathy and in whom roxadustat was switched to daprodustat (another HIF-PH inhibitor) due to the onset of central hypothyroidism. About three weeks after this change, the patient developed acute asymptomatic cerebral infarction with an elevation of hemoglobin (Hb). It is unclear if the change to daprodustat was involved in the onset of cerebral infarction. However, this case suggests that particular caution should be paid to unexpected acute elevation of Hb after a change from one HIF-PH inhibitor to another, especially in a patient at high risk for cardiovascular events.</description><subject>Anemia</subject><subject>Antibodies</subject><subject>Asymptomatic</subject><subject>Blood tests</subject><subject>Creatinine</subject><subject>Diabetes</subject><subject>Diabetic nephropathy</subject><subject>Endocrinology/Diabetes/Metabolism</subject><subject>Hemoglobin</subject><subject>Hospitalization</subject><subject>Hypertension</subject><subject>Internal Medicine</subject><subject>Iron</subject><subject>Laboratories</subject><subject>Magnetic resonance imaging</subject><subject>Metabolic disorders</subject><subject>Pituitary gland</subject><subject>Stroke</subject><subject>Thrombosis</subject><subject>Thyroid gland</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkUFv1DAQhSMEolXpjTOyxIUDW8ZxEtsntFpaqFQJVEAcrYkz7rra2IvtQPn3ZNmlKpxmRvPp6T29qnrO4UzKVr-xU6Ipn3VCN_Wj6rjmnVoorprHD_aj6jTnWwDgIGuQ8LQ6EkrLRuj2uMIVJeoTbthlcJhs8TGwpSuU2Oefvti1DzfsIsWRXcc7HKZcsLAS2Tvcpng4fWDIPmHxFAr75suaXVOYFZeBRo_PqicON5lOD_Ok-npx_mX1YXH18f3lanm1sAKgLDgHch21egAk5WoHtWuGHnWPODREFnTTkxgahaAGDaKnQTiUaFutqFHipHq7191O_UiDnc3Mscw2-RHTLxPRm38_wa_NTfxhOK9rCVLOCq8OCil-nygXM_psabPBQHHKRoDsZNeqdoe-_A-9jVOaQ-8o1XVSa8Fn6vWesinmnMjdu-Fgdv2ZfX_mT38z_uJhgnv4b1viN1ZsmWg</recordid><startdate>20240706</startdate><enddate>20240706</enddate><creator>Takebayashi, Kohzo</creator><creator>Yamauchi, Mototaka</creator><creator>Hara, Kenji</creator><creator>Tsuchiya, Takafumi</creator><creator>Hashimoto, Koshi</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240706</creationdate><title>Cerebral Infarction After Switching From Roxadustat to Daprodustat in a Patient With Renal Anemia</title><author>Takebayashi, Kohzo ; Yamauchi, Mototaka ; Hara, Kenji ; Tsuchiya, Takafumi ; Hashimoto, Koshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-110ef6e59d0ae8f2f02f4dba9baad4eec094be3d48a08d903bed3fa7ac598e483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anemia</topic><topic>Antibodies</topic><topic>Asymptomatic</topic><topic>Blood tests</topic><topic>Creatinine</topic><topic>Diabetes</topic><topic>Diabetic nephropathy</topic><topic>Endocrinology/Diabetes/Metabolism</topic><topic>Hemoglobin</topic><topic>Hospitalization</topic><topic>Hypertension</topic><topic>Internal Medicine</topic><topic>Iron</topic><topic>Laboratories</topic><topic>Magnetic resonance imaging</topic><topic>Metabolic disorders</topic><topic>Pituitary gland</topic><topic>Stroke</topic><topic>Thrombosis</topic><topic>Thyroid gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takebayashi, Kohzo</creatorcontrib><creatorcontrib>Yamauchi, Mototaka</creatorcontrib><creatorcontrib>Hara, Kenji</creatorcontrib><creatorcontrib>Tsuchiya, Takafumi</creatorcontrib><creatorcontrib>Hashimoto, Koshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takebayashi, Kohzo</au><au>Yamauchi, Mototaka</au><au>Hara, Kenji</au><au>Tsuchiya, Takafumi</au><au>Hashimoto, Koshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebral Infarction After Switching From Roxadustat to Daprodustat in a Patient With Renal Anemia</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2024-07-06</date><risdate>2024</risdate><volume>16</volume><issue>7</issue><spage>e63942</spage><pages>e63942-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Renal anemia is generally caused by a decrease in the production of erythropoietin in kidney due to renal dysfunction, and this may be associated with the increase in mortality and cardiovascular events in addition to subjective symptoms such as fatigue and wobbliness. We report a case of an 87-year-old man with type 2 diabetes, hypertension, and dyslipidemia who had received roxadustat (a hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor) for renal anemia due to diabetic nephropathy and in whom roxadustat was switched to daprodustat (another HIF-PH inhibitor) due to the onset of central hypothyroidism. About three weeks after this change, the patient developed acute asymptomatic cerebral infarction with an elevation of hemoglobin (Hb). It is unclear if the change to daprodustat was involved in the onset of cerebral infarction. However, this case suggests that particular caution should be paid to unexpected acute elevation of Hb after a change from one HIF-PH inhibitor to another, especially in a patient at high risk for cardiovascular events.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>38974395</pmid><doi>10.7759/cureus.63942</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2024-07, Vol.16 (7), p.e63942 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11227077 |
| source | PubMed Central; PubMed Central Open Access |
| subjects | Anemia Antibodies Asymptomatic Blood tests Creatinine Diabetes Diabetic nephropathy Endocrinology/Diabetes/Metabolism Hemoglobin Hospitalization Hypertension Internal Medicine Iron Laboratories Magnetic resonance imaging Metabolic disorders Pituitary gland Stroke Thrombosis Thyroid gland |
| title | Cerebral Infarction After Switching From Roxadustat to Daprodustat in a Patient With Renal Anemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T22%3A41%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebral%20Infarction%20After%20Switching%20From%20Roxadustat%20to%20Daprodustat%20in%20a%20Patient%20With%20Renal%20Anemia&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Takebayashi,%20Kohzo&rft.date=2024-07-06&rft.volume=16&rft.issue=7&rft.spage=e63942&rft.pages=e63942-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.63942&rft_dat=%3Cproquest_pubme%3E3076765857%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3086679931&rft_id=info:pmid/38974395&rfr_iscdi=true |